newsfilter
← Latest News
Business Wire·

CEL-SCI Announces Pricing of $5 Million Public Offering

CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 16,130,000 shares of its common stock (or pre-funded